Advertisement

Advertisement

Lymphoma

Expert Point of View: Peter Martin, MD

“With current therapies, the median survival for people with follicular lymphoma [FL] is about 20 years. Most people with FL will live as long as the general population, as it is a disease of morbidity more than mortality. That said, there is still room for improvement,” said formal CHRONOS-3...

Lymphoma

CHRONOS-3: Addition of Copanlisib to Rituximab Extends Progression-Free Survival in Relapsed Indolent NHL

The combination of the PI3K inhibitor copanlisib plus the monoclonal antibody rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (NHL), according to the results of the phase III CHRONOS-3...

Lymphoma

Diagnosis-to-Treatment Interval and Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

In a study reported in the Journal of Clinical Oncology, Stefan Alig, MD, and colleagues found that a short diagnosis-to-treatment interval in patients with diffuse large B-cell lymphoma (DLBCL) was associated with higher baseline tumor burden, reflected in higher pretreatment circulating tumor DNA ...

Lymphoma
Immunotherapy

Brentuximab Vedotin Plus Chemotherapy in Newly Diagnosed Early-Stage Unfavorable-Risk Hodgkin Lymphoma

In a pilot study reported in the Journal of Clinical Oncology, Kumar et al found that the combination of brentuximab vedotin with AVD (doxorubicin, vinblastine, and dacarbazine) was highly active in patients with newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma and may permit the...

Lymphoma
Immunotherapy

FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma

On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, ...

Lymphoma

Umbralisib for Previously Treated Relapsed or Refractory Marginal Zone Lymphoma and Follicular Lymphoma

On February 5, 2021, umbralisib was granted accelerated approval for the following indications: adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti–CD20-based regimen and adult patients with relapsed or refractory follicular lymphoma who have...

Lymphoma
Immunotherapy

Glofitamab for Relapsed or Refractory B-Cell Lymphoma

In a phase I trial reported in the Journal of Clinical Oncology, Hutchings et al found that the bivalent CD20-targeting T-cell–engaging bispecific antibody glofitamab produced high response rates and was associated with manageable toxicity in patients with predominantly refractory aggressive B-cell ...

Lymphoma
Immunotherapy

Integration of Brentuximab Vedotin Into Front-Line Treatment for Pediatric Patients With High-Risk Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Metzger et al found that the integration of brentuximab vedotin into front-line treatment of pediatric patients with high-risk classical Hodgkin lymphoma resulted in avoidance of radiotherapy in many patients, as well as high rates of...

lymphoma

Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CHRONOS-3 trial, which showed that copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (Abstract CT001).

Lymphoma

Copanlisib/Rituximab Extends Progression-Free Survival vs Rituximab/Placebo in Indolent Non-Hodgkin Lymphoma

The combination of copanlisib plus rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with indolent non-Hodgkin lymphoma, according to results of the phase III CHRONOS-3 trial presented by Matthew J. Matasar, MD, at the virtual...

Lymphoma
Immunotherapy

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy was well tolerated and showed signs of clinical efficacy in patients with relapsed/refractory B-cell lymphoma, according to phase I clinical trial data presented by Ghafouri et al during week 1 of the virtual American...

leukemia
lymphoma

Jennifer R. Brown, MD, PhD, on Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses treatment choices for patients with relapsed or refractory CLL/SLL, when to stop therapy due to adverse events, BTK inhibitors and their second-generation counterparts, the need for ways to manage disease progression on novel drugs, and minimal residual disease as a predictor of response.

Lymphoma
Immunotherapy

Pembrolizumab vs Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma: KEYNOTE-204 Trial

As reported in The Lancet Oncology by John Kuruvilla, MD, and colleagues, an interim analysis of the phase III KEYNOTE-204 trial has shown significantly improved progression-free survival with pembrolizumab vs brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma....

Lymphoma
Immunotherapy

Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin

“I was taught that the way of progress was neither swift nor easy.” —Marie Curie To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two abstracts selected from the meeting proceedings focusing on...

Hematologic Malignancies
Leukemia
Lymphoma

Noncovalent BTK Inhibitor Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies

In the phase I/II BRUIN trial reported in The Lancet, Anthony R. Mato, MD, and colleagues found that the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with relapsed or refractory B-cell malignancies, including those previously treated with ...

Lymphoma

Umbralisib for Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology by Nathan H. Fowler, MD, and colleagues, the phase IIb UNITY-NHL trial has shown that the dual PI3Kδ/casein kinase (CK) 1ε inhibitor umbralisib produced durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma. The study ...

Lymphoma

ROBUST Trial: Addition of Lenalidomide to R-CHOP in Previously Untreated ABC-Type DLBCL

As reported in the Journal of Clinical Oncology by Grzegorz S. Nowakowski, MD, and colleagues, the phase III ROBUST trial showed that the addition of lenalidomide to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP) did not significantly improve...

Lymphoma
Survivorship

Effect of Risk-Adapted Therapy on Long-Term Morbidity in Pediatric Patients With Hodgkin Lymphoma

In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Kevin C. Oeffinger, MD, and colleagues found that adoption of risk-adapted therapy in the 1990s was associated with reduced risk of serious chronic health conditions in pediatric Hodgkin lymphoma...

Lymphoma

Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive Anaplastic Large Cell Lymphoma

On January 14, 2021, crizotinib was approved for treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.1,2 The safety and efficacy of crizotinib have not been established in older...

Lymphoma
Immunotherapy

FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

On March 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to axicabtagene ciloleucel (Yescarta) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. ZUMA-5 Approval in follicular lymphoma was based on a...

Lymphoma
Immunotherapy

Five-Year Outcomes With Tisagenlecleucel in Patients With Relapsed or Refractory B-Cell Lymphomas

As reported in a letter to the editor in The New England Journal of Medicine by Elise A. Chong, MD, and colleagues, long-term follow-up of a single-center trial of tisagenlecleucel showed maintained responses in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ...

Lymphoma
COVID-19

Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma

Patients with lymphoma hospitalized for severe COVID-19 infection were at higher risk for prolonged hospital stay and death if they were treated with B-cell–depleting therapies (eg, rituximab, obinutuzumab) within the previous 12 months. The risk of persistent COVID-19 infection was also higher in...

Lymphoma
Immunotherapy

B-Cell and T-Cell Non-Hodgkin Lymphomas

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...

Lymphoma

Addition of Lenalidomide to R-CHOP in Newly Diagnosed Patients With DLBCL

In a phase II signal-seeking trial (ECOG-ACRIN E1412) reported in the Journal of Clinical Oncology, Grzegorz S. Nowakowski, MD, and colleagues found that the addition of lenalidomide (R) to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2CHOP) improved outcomes...

Lymphoma

PET-Guided Omission of Consolidation Radiotherapy in Early-Stage Unfavorable Hodgkin Lymphoma

In a phase III German Hodgkin Study Group trial (GHSG HD17) reported in The Lancet Oncology, Peter Borchmann, MD, and colleagues found that positron-emission tomography (PET)-guided omission of consolidation radiotherapy was associated with noninferior progression-free survival among patients with...

Leukemia
Lymphoma

Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL

Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s tyrosine kinase (BTK) inhibitors and BCL2...

Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma

Novel Therapies and New Indications for Use in Treatment of Hematologic Malignancies

Selinexor: On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Venetoclax: On October 16,...

Lymphoma
Immunotherapy

Expert Point of View: Marco Ruella, MD

Marco Ruella, MD, of Perelman School of Medicine and Scientific Director of the Lymphoma Program, University of Pennsylvania, commented on this study on CD58 aberrations: “This is a very important study because it describes a possible new mechanism for relapse after CAR-T19 immunotherapy in...

Lymphoma
Immunotherapy

Overcoming CD58 Loss May Be Promising Path to Overcoming Resistance to CAR T-Cell Therapies

Engineering chimeric antigen receptor (CAR) T cells to overcome CD58 loss may be a way to boost responses in patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to treatment with axicabtagene ciloleucel and other CAR T-cell therapies, according to a study presented at the 2020...

Lymphoma
Immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other chimeric antigen receptor (CAR) T-cell products being...

Lymphoma
Immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...

Leukemia
Lymphoma
Multiple Myeloma
Immunotherapy

ASH 2020 Meeting Highlights

The world of hematologic malignancies continues to move forward at a robust pace despite the challenges of the COVID era. Although some areas of clinical trials and basic research suffered short-term stoppages or delays due to the pandemic, the studies presented at the 2020 American Society of...

Lymphoma
Immunotherapy

Effect of Organ Function–Based Eligibility Criteria on Clinical Trial Enrollment for Patients With DLBCL

In a study reported in the Journal of Clinical Oncology, Khurana et al found that up to 24% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) receiving standard immunochemotherapy are excluded from participation in clinical trials on the basis of organ function eligibility...

Lymphoma

Optimal Radiotherapy Dose for Follicular and Marginal Zone Lymphomas: 24 vs 4 Gy

As reported in The Lancet Oncology by Peter Hoskin, MD, and colleagues, 5-year follow-up of the phase III noninferiority FoRT trial showed that radiotherapy at 24 vs 4 Gy continued to be associated with superior freedom from local disease progression in patients with follicular or marginal zone...

Lymphoma

Expert Point of View: Deepa Jagadeesh, MD, MPH

In commenting on the results of the phase II PRIMO trial of the PI3K inhibitor duvelisib by Pro et al, Deepa Jagadeesh, MD, MPH, Assistant Professor, Cleveland Clinic Lerner College of Medicine, Lymphoma and Bone Marrow Transplant Program, and Taussig Cancer Institute, observed that while response...

Lymphoma

Phase II PRIMO Dose-Optimization Trial of Duvelisib in Peripheral T-Cell Lymphoma

Researchers at the ASH Annual Meeting and Exposition reported high response rates in patients with relapsed peripheral T-cell lymphoma after treatment with single-agent duvelisib, a dual PI3K inhibitor.1  Barbara Pro, MD, of Robert H. Lurie Comprehensive Cancer Center, Northwestern University...

Lymphoma

Expert Point of View: Deepa Jagadeesh, MD, MPH

“Although some B-cell lymphomas are highly curable, this goal remains elusive for most T-cell lymphomas (TCL). Refractory and relapsed disease post induction therapy remains a major challenge in management,” said Deepa Jagadeesh, MD, MPH, Assistant Professor, Cleveland Clinic Lerner College of...

Lymphoma

Allogeneic Stem Cell Transplant Improves Survival in Peripheral T-Cell Lymphoma

In a large retrospective analysis of allogeneic transplant for relapsed or refractory peripheral T-cell lymphoma (PTCL), more than half the patients studied were alive at 5 years, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 “In the...

Lymphoma
Immunotherapy

Expert Point of View: James Essell, MD

James Essell, MD, Medical Director of the Blood Cancer Center, The Jewish Hospital-Mercy Health Cincinnati Cancer and Cellular Therapy Center, and Chair of Cellular Therapy, observed that axicabtagene ciloleucel compares favorably with other CAR T-cell products being evaluated for indolent...

Lymphoma
Immunotherapy

ZUMA-5: Axicabtagene Ciloleucel Elicits Response in Indolent Non-Hodgkin Lymphoma

In the phase II ZUMA-5 trial, the cellular immunotherapy axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma (NHL), researchers reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Axicabtagene ciloleucel has improved ...

Lymphoma
Immunotherapy

Lisocabtagene Maraleucel Approved by FDA for Patients With Relapsed or Refractory Large B-Cell Lymphoma

On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not...

Lymphoma

FDA Grants Accelerated Approval to Umbralisib for Treatment of Marginal Zone and Follicular Lymphomas

On February 5, the U.S. Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq), a kinase inhibitor including PI3K-delta and CK1-epsilon, for the following indications: Adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior...

Lymphoma
COVID-19
Immunotherapy

Patients With Lymphoma Receiving B-Cell–Depleting Therapies May Be at Greater Risk for Persistent COVID-19 Infection

B-cell–depleting immunotherapy may cause B-cell aplasia and impair the body’s immune response. A retrospective, multicentric French study of patients with lymphoma and persistent COVID-19 infection has found that those treated with B-cell–depleting therapies within the previous 12 months had nearly ...

Lymphoma

New Burkitt Lymphoma International Prognostic Index

As reported by Olszewski et al in the Journal of Clinical Oncology, members of The Burkitt Lymphoma International Prognostic Index Consortium have developed an index—the Burkitt Lymphoma International Prognostic Index (BL-IPI)—that provides “robust discrimination of survival” among adult patients...

Lymphoma
Geriatric Oncology

Lenalidomide Plus Subcutaneous Rituximab-MiniCHOP in Patients Aged 80 or Older With DLBCL

In the French phase III SENIOR trial reported in the Journal of Clinical Oncology, Oberic et al found that the addition of lenalidomide to subcutaneous rituximab plus attenuated-dose CHOP (mini-CHOP; cyclophosphamide, doxorubicin, vincristine, prednisone) did not improve overall survival in...

Lymphoma

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

On January 14, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for pediatric patients aged 1 year and older and young adults with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been ...

hematologic malignancies
lymphoma
multiple myeloma
issues in oncology
palliative care

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Lena E. Winestone, MD, MSHP, of the University of California, San Francisco and Benioff Children’s Hospital, reviews different aspects of bias in treatment delivery, including patient selection for clinical trials; racial and ethnic disparities in survival for indolent non-Hodgkin diffuse large B-cell lymphomas; and end-of-life hospitalization of patients with multiple myeloma, as well as outcome disparities (Abstracts 207-212).

lymphoma

Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II data from the Primo trial, which support continued evaluation of duvelisib as a treatment option for relapsed or refractory peripheral T-cell lymphoma due to consistent response rates (Abstract 44).

lymphoma

Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

Tycel J. Phillips, MD, of the University of Michigan Rogel Cancer Center, discusses phase II data from the CITADEL-204 study, showing that patients with relapsed or refractory marginal zone lymphoma who were not previously treated with a Bruton’s tyrosine kinase inhibitor achieved rapid and durable responses with single-agent parsaclisib. Comparable results were also observed in patients with nodal, extranodal, or splenic disease (Abstract 338).

lymphoma

Steven M. Horwitz, MD, on T-Cell Lymphoma: Update on Allogeneic Hematopoietic Transplant

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses data from the largest multicenter retrospective analysis of allogeneic hematopoietic transplantation, which supports its curative potential in patients with mature T-cell lymphoma, a group marked by poor survival and limited treatment options (Abstract 41).

Advertisement

Advertisement

Advertisement